Entries by Nascent

Nascent Biotech, Inc. Announces the Addition of Mr. Doug Karas to its Board of Directors

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors. Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting […]

Nascent Biotech Inc. Announces the Retirement of Its Convertible Debt

San Diego, CA September 17, 2015 – Nascent Biotech, Inc, (“Nascent” or “the Company”) (PINK.BB: NBIO) is pleased to announce that it has retired the $ 60,000 convertible debenture effective yesterday. The convertible debt could have potentially been converted into 6,000,000 shares of the Company’s common stock, thus diluting all the shareholders by nearly 30%. […]

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, to support the filing of an Investigational New Drug exemption (IND). Pritumumab is a fully human […]

Nascent Biotech, Inc. President Interviewed by The Stock Radio

San Diego, CA August 12, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), is pleased to release a recent interview with company President Sean Carrick, on The Stock Radio show.  It can be heard in full at: http://thestockradio.com/otcpink-nbio-nascent-biotech-inc-president-sean-carrick-2239.html In the interview, Mr. Carrick details that Nascent Biotech’s primary asset, Pritumumab, binds to a […]

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its scientific advisory board: Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories […]

Nascent Biotech, Inc. Begins Toxicology Trials

San Diego, CA, June 4th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) Nascent Biotech, Inc announced that it has begun toxicology trials on its primary asset Pritumumab, a monoclonal antibody directed against a novel antigenic target on cancer cells. Pritumumab, a natural human IgG1 antibody, had been previously studied in brain cancer patients 20 years ago […]

Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical

San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) grant, titled “Novel Immunotherapy for Brain Cancer,” to fund initial development of tobacco plants as an adjunct expression system for Nascent Biotech’s lead candidate biopharmaceutical, Pritumumab, a […]